A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in bone tissue, offering a potential new treatment target for patients with ...

Benign prostatic hyperplasia (BPH) is a common condition in aging men, leading to lower urinary tract symptoms (LUTS) that affect quality of life. Treatment options have evolved from invasive ...

DEAR DR. ROACH: I have been treated for prostate cancer and stopped my semiannual Eligard injections three years ago. I’m 75 years old and about 5 feet, 9 inches tall. Before treatment, I weighed 227 ...

We aimed to describe the technique and outcomes of "Double Rings" En-bloc thulium fiber laser enucleation of the prostate (ThuFLEP) with early anatomical apical release in benign prostatic hyperplasia ...

Former President Joe Biden was diagnosed with an "aggressive form" of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president's prostate cancer is characterized ...

Our skin and mucous membranes are protected by epithelial cells. This 'barrier' tissue performs its function thanks to specialized structures called 'junctions'. They ensure cell cohesion and regulate ...

Penn's School of Dental Medicine, the School of Engineering and Applied Science, and Perelman School of Medicine have worked together to create a new treatment option for apical periodontitis, a ...

High pre-treatment PSA levels correlate with increased recurrence and treatment failure in intermediate-risk prostate cancer patients treated with HIFU. Gleason grade 3 or higher is associated with ...

AngioDynamics, Inc. ANGO, yesterday, announced the receipt of the FDA’s 510(k) clearance for the NanoKnife System for prostate tissue ablation. The clearance for the NanoKnife System for prostate ...

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...